{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:04:14Z","timestamp":1759565054540,"version":"3.37.3"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T00:00:00Z","timestamp":1629763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T00:00:00Z","timestamp":1629763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010740","name":"Asahi Kasei Pharma Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010740","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although changes in serum sclerostin levels at 12\u00a0months after infusion of zoledronic acid have been reported, the changes in sclerostin levels at earlier time points are poorly understood. We reanalyzed the study data of a previous phase 1 pharmacokinetic study and investigated the correlation between changes in sclerostin levels and relevant factors in calcium metabolism. A total of 24 Japanese female subjects with primary postmenopausal osteoporosis were administered a single 4- or 5-mg dose of zoledronic acid. Serum and urine samples were collected on days 15, 29, 90, 180, and 365 after administration. Serum levels of calcium, phosphate, intact parathyroid hormone (iPTH), and sclerostin were measured. Levels of serum sclerostin were unchanged from baseline on days 15 and 29, but increased significantly on day 90, subsequently decreased significantly on day 180, and returned to baseline levels on day 365. A significant negative correlation was observed between changes in iPTH levels at early time points and sclerostin levels at later time points. This suggests that sclerostin was negatively regulated by iPTH, and the decrease in sclerostin may indicate the start of bone formation during later time points after zoledronic acid injection.<\/jats:p>","DOI":"10.1007\/s00223-021-00900-w","type":"journal-article","created":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T14:04:41Z","timestamp":1629813881000},"page":"87-92","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Relationship Between Changes in Serum Levels of Intact Parathyroid Hormone and Sclerostin After a Single Dose of Zoledronic Acid: Results of a Phase 1 Pharmacokinetic Study"],"prefix":"10.1007","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2261-309X","authenticated-orcid":false,"given":"Tatsuhiko","family":"Kuroda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6599-6185","authenticated-orcid":false,"given":"Masataka","family":"Shiraki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshitaka","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8005-9659","authenticated-orcid":false,"given":"Hiroaki","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9368-9614","authenticated-orcid":false,"given":"Kazuki","family":"Hiraishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0627-1816","authenticated-orcid":false,"given":"Toshitsugu","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8192-5125","authenticated-orcid":false,"given":"Satoshi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,24]]},"reference":[{"key":"900_CR1","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.bone.2005.05.003","volume":"38","author":"GH Nancollas","year":"2006","unstructured":"Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A et al (2006) Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38:617\u2013627. https:\/\/doi.org\/10.1016\/j.bone.2005.05.003","journal-title":"Bone"},{"key":"900_CR2","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/j.1532-5415.2009.02673.x","volume":"58","author":"S Boonen","year":"2010","unstructured":"Boonen S, Black DM, Col\u00f3n-Emeric CS, Eastell R, Magaziner JS, Eriksen EF, Mesenbrink P et al (2010) Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc 58:292\u2013299. https:\/\/doi.org\/10.1111\/j.1532-5415.2009.02673.x","journal-title":"J Am Geriatr Soc"},{"key":"900_CR3","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1056\/NEJMoa011807","volume":"346","author":"IR Reid","year":"2002","unstructured":"Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A et al (2002) Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 346:653\u2013661. https:\/\/doi.org\/10.1056\/NEJMoa011807","journal-title":"N Engl J Med"},{"key":"900_CR4","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F et al (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809\u20131822. https:\/\/doi.org\/10.1056\/NEJMoa067312","journal-title":"N Engl J Med"},{"key":"900_CR5","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/s00198-016-3736-y","volume":"28","author":"T Nakamura","year":"2017","unstructured":"Nakamura T, Fukunaga M, Nakano T, Kishimoto H, Ito M, Hagino H, Sone T et al (2017) Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study). Osteoporos Int 28:389\u2013398. https:\/\/doi.org\/10.1007\/s00198-016-3736-y","journal-title":"Osteoporos Int"},{"key":"900_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00223-013-9774-y","volume":"94","author":"T Bellido","year":"2014","unstructured":"Bellido T (2014) Osteocyte-driven bone remodeling. Calcif Tissue Int 94:25\u201334. https:\/\/doi.org\/10.1007\/s00223-013-9774-y","journal-title":"Calcif Tissue Int"},{"key":"900_CR7","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.bone.2016.11.024","volume":"96","author":"MM Weivoda","year":"2017","unstructured":"Weivoda MM, Youssef SJ, Oursler MJ (2017) Sclerostin expression and functions beyond the osteocyte. Bone 96:45\u201350. https:\/\/doi.org\/10.1016\/j.bone.2016.11.024","journal-title":"Bone"},{"key":"900_CR8","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00223-013-9749-z","volume":"93","author":"M Rossini","year":"2013","unstructured":"Rossini M, Gatti D, Adami S (2013) Involvement of WNT\/\u03b2-catenin signaling in the treatment of osteoporosis. Calcif Tissue Int 93:121\u2013132. https:\/\/doi.org\/10.1007\/s00223-013-9749-z","journal-title":"Calcif Tissue Int"},{"key":"900_CR9","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.bone.2011.11.028","volume":"50","author":"D Gatti","year":"2012","unstructured":"Gatti D, Viapiana O, Adami S, Idolazzi L, Fracassi E, Rossini M (2012) Bisphosphonate treatment of postmenopausal osteoporosis is associated with a dose dependent increase in serum sclerostin. Bone 50:739\u2013742. https:\/\/doi.org\/10.1016\/j.bone.2011.11.028","journal-title":"Bone"},{"key":"900_CR10","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1002\/jbmr.1681","volume":"27","author":"D Gatti","year":"2012","unstructured":"Gatti D, Viapiana O, Fracassi E, Idolazzi L, Dartizio C, Povino MR, Adami S et al (2012) Sclerostin and DKK1 in postmenopausal osteoporosis treated with denosumab. J Bone Miner Res 27:2259\u20132263. https:\/\/doi.org\/10.1002\/jbmr.1681","journal-title":"J Bone Miner Res"},{"key":"900_CR11","doi-asserted-by":"publisher","first-page":"5056","DOI":"10.1210\/jc.2010-0720","volume":"95","author":"MT Drake","year":"2010","unstructured":"Drake MT, Srinivasan B, M\u00f6dder UI, Peterson JM, McCready LK, Riggs BL, Dwyer D et al (2010) Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J Clin Endocrinol Metab 95:5056\u20135062. https:\/\/doi.org\/10.1210\/jc.2010-0720","journal-title":"J Clin Endocrinol Metab"},{"key":"900_CR12","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1007\/s00198-011-1675-1","volume":"23","author":"YE Chung","year":"2012","unstructured":"Chung YE, Lee SH, Lee SY, Kim S-Y, Kim H-H, Mirza FS, Lee S-K et al (2012) Long-term treatment with raloxifene, but not bisphosphonates, reduces circulating sclerostin levels in postmenopausal women. Osteoporos Int 23:1235\u20131243. https:\/\/doi.org\/10.1007\/s00198-011-1675-1","journal-title":"Osteoporos Int"},{"key":"900_CR13","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1210\/jc.2012-4039","volume":"98","author":"A Catalano","year":"2013","unstructured":"Catalano A, Morabito N, Basile G, Brancatelli S, Cucinotta D, Lasco A (2013) Zoledronic acid acutely increases sclerostin serum levels in women with postmenopausal osteoporosis. J Clin Endocrinol Metab 98:1911\u20131915. https:\/\/doi.org\/10.1210\/jc.2012-4039","journal-title":"J Clin Endocrinol Metab"},{"key":"900_CR14","doi-asserted-by":"publisher","first-page":"3206","DOI":"10.1210\/jc.2013-1402","volume":"98","author":"AD Anastasilakis","year":"2013","unstructured":"Anastasilakis AD, Polyzos SA, Gkiomisi A, Bisbinas I, Gerou S, Makras P (2013) Comparative effect of zoledronic acid versus denosumab on serum sclerostin and dickkopf-1 levels of naive postmenopausal women with low bone mass: a randomized, head-to-head clinical trial. J Clin Endocrinol Metab 98:3206\u20133212. https:\/\/doi.org\/10.1210\/jc.2013-1402","journal-title":"J Clin Endocrinol Metab"},{"key":"900_CR15","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.bone.2014.06.037","volume":"67","author":"D Gatti","year":"2014","unstructured":"Gatti D, Viapiana O, Idolazzi L, Fracassi E, Ionescu C, Dartizio C, Troplini S et al (2014) Distinct effect of zoledronate and clodronate on circulating levels of DKK1 and sclerostin in women with postmenopausal osteoporosis. Bone 67:189\u2013192. https:\/\/doi.org\/10.1016\/j.bone.2014.06.037","journal-title":"Bone"},{"key":"900_CR16","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1007\/s00198-015-3174-2","volume":"26","author":"AD Anastasilakis","year":"2015","unstructured":"Anastasilakis AD, Polyzos SA, Gkiomisi A, Saridakis ZG, Digkas D, Bisbinas I, Sakellariou GT et al (2015) Denosumab versus zoledronic acid in patients previously treated with zoledronic acid. Osteoporos Int 26:2521\u20132527. https:\/\/doi.org\/10.1007\/s00198-015-3174-2","journal-title":"Osteoporos Int"},{"key":"900_CR17","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00774-016-0806-3","volume":"35","author":"M Shiraki","year":"2017","unstructured":"Shiraki M, Tanaka S, Suzuki H, Ueda S, Nakamura T (2017) Safety, pharmacokinetics, and changes in bone metabolism associated with zoledronic acid treatment in Japanese patients with primary osteoporosis. J Bone Miner Metab 35:675\u2013684. https:\/\/doi.org\/10.1007\/s00774-016-0806-3","journal-title":"J Bone Miner Metab"},{"key":"900_CR18","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s007740170001","volume":"19","author":"H Orimo","year":"2001","unstructured":"Orimo H, Hayashi Y, Fukunaga M, Sone T, Fujiwara S, Shiraki M, Kushida K et al (2001) Diagnostic criteria for primary osteoporosis: year 2000 revision. J Bone Miner Metab 19:331\u2013337. https:\/\/doi.org\/10.1007\/s007740170001","journal-title":"J Bone Miner Metab"},{"key":"900_CR19","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00223-015-0003-8","volume":"96","author":"C Muschitz","year":"2015","unstructured":"Muschitz C, Kocijan R, Pahr D, Patsch JM, Amrein K, Misof BM, Kaider A et al (2015) Ibandronate increases sclerostin levels and bone strength in male patients with idiopathic osteoporosis. Calcif Tissue Int 96:477\u2013489. https:\/\/doi.org\/10.1007\/s00223-015-0003-8","journal-title":"Calcif Tissue Int"},{"key":"900_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.bone.2013.12.017","volume":"61","author":"S Gonnelli","year":"2014","unstructured":"Gonnelli S, Caffarelli C, Tanzilli L, Pondrelli C, Lucani B, Franci BM, Nuti R (2014) Effects of intravenous zoledronate and ibandronate on carotid intima-media thickness, lipids and FGF-23 in postmenopausal osteoporotic women. Bone 61:27\u201332. https:\/\/doi.org\/10.1016\/j.bone.2013.12.017","journal-title":"Bone"},{"key":"900_CR21","doi-asserted-by":"publisher","first-page":"4577","DOI":"10.1210\/en.2005-0239","volume":"146","author":"T Bellido","year":"2005","unstructured":"Bellido T, Ali AA, Gubrij I, Plotkin LI, Fu Q, O\u2019Brien CA, Manolagas SC et al (2005) Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146:4577\u20134583. https:\/\/doi.org\/10.1210\/en.2005-0239","journal-title":"Endocrinology"},{"key":"900_CR22","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s10735-007-9096-3","volume":"38","author":"G Silvestrini","year":"2007","unstructured":"Silvestrini G, Ballanti P, Leopizzi M, Sebastiani M, Berni S, Di Vito M, Bonucci E (2007) Effects of intermittent parathyroid hormone (PTH) administration on SOST mRNA and protein in rat bone. J Mol Histol 38:261\u2013269. https:\/\/doi.org\/10.1007\/s10735-007-9096-3","journal-title":"J Mol Histol"},{"key":"900_CR23","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1007\/s00223-012-9665-7","volume":"92","author":"O Viapiana","year":"2013","unstructured":"Viapiana O, Fracassi E, Troplini S, Idolazzi L, Rossini M, Adami S, Gatti D (2013) Sclerostin and DKK1 in primary hyperparathyroidism. Calcif Tissue Int 92:324\u2013329. https:\/\/doi.org\/10.1007\/s00223-012-9665-7","journal-title":"Calcif Tissue Int"},{"key":"900_CR24","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1517\/14728222.2014.983078","volume":"19","author":"AD Anastasilakis","year":"2015","unstructured":"Anastasilakis AD, Polyzos SA, Makras P, Gkiomisi A, Sakellariou G, Savvidis M, Papatheodorou A et al (2015) Circulating semaphorin-4D and plexin-B1 levels in postmenopausal women with low bone mass: the 3-month effect of zoledronic acid, denosumab or teriparatide treatment. Expert Opin Ther Targets 19:299\u2013306. https:\/\/doi.org\/10.1517\/14728222.2014.983078","journal-title":"Expert Opin Ther Targets"},{"key":"900_CR25","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1007\/s00223-017-0272-5","volume":"101","author":"ME Pickering","year":"2017","unstructured":"Pickering ME, Simon M, Sornay-Rendu E, Chikh K, Carlier MC, Raby AL, Szulc P et al (2017) Serum sclerostin increases after acute physical activity. Calcif Tissue Int 101:170\u2013173. https:\/\/doi.org\/10.1007\/s00223-017-0272-5","journal-title":"Calcif Tissue Int"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-021-00900-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-021-00900-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-021-00900-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,5]],"date-time":"2022-01-05T19:10:20Z","timestamp":1641409820000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-021-00900-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,24]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["900"],"URL":"https:\/\/doi.org\/10.1007\/s00223-021-00900-w","relation":{},"ISSN":["0171-967X","1432-0827"],"issn-type":[{"type":"print","value":"0171-967X"},{"type":"electronic","value":"1432-0827"}],"subject":[],"published":{"date-parts":[[2021,8,24]]},"assertion":[{"value":"22 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tatsuhiko Kuroda is an employee of Asahi Kasei Corporation. Masataka Shiraki has received consulting fees from Asahi Kasei Pharma Corporation, MSD, and Teijin Pharma and lecture fees from Astellas Pharma, Chugai Pharmaceutical, Daiichi Sankyo, Eisai, Eli Lilly Japan, Ono Pharmaceutical, and Pfizer. Toshitaka Nakamura has received consulting fees from Asahi Kasei Pharma Corporation, Amgen, Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly Japan, MSD, Taisho Toyama Pharmaceutical, and Teijin Pharma. Hiroaki Suzuki, Kazuki Hiraishi, and Satoshi Tanaka are employees of Asahi Kasei Pharma Corporation. Toshitsugu Sugimoto has received research grants and\/or consulting fees from Astellas Pharma, Eisai, Daiichi Sankyo, Chugai Pharmaceutical, and Eli Lilly Japan as well as consulting and\/or lecture fees from Asahi Kasei Pharma Corporation and Daiichi Sankyo.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in compliance with the World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects and Good Clinical Practice. The protocol was reviewed by the institutional review board at each study site.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Written informed consent was obtained from all individual subjects before enrollment in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All participants gave their written informed consent for the publication of the data in an anonymized form.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Publish"}}]}}